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Abstract
Rationale: Improving the prospective identification of patients with
systemic inflammatory response syndrome (SIRS) and sepsis at low
risk for organ dysfunction and death is a major clinical challenge.
Objectives: To develop and validate a multibiomarker-based
prediction model for 28-day mortality in critically ill patients with
SIRS and sepsis.
Methods: A derivation cohort (n = 888) and internal test cohort
(n = 278)were taken fromaprospective study of critically ill intensive
care unit (ICU) patients meeting two of four SIRS criteria at an
academic medical center for whom plasma was obtained within
24 hours. The validation cohort (n = 759) was taken from a
prospective cohort enrolled at another academic medical center ICU
for whom plasma was obtained within 48 hours. We measured
concentrations of angiopoietin-1, angiopoietin-2, IL-6, IL-8, soluble
tumor necrosis factor receptor-1, soluble vascular cell adhesion
molecule-1, granulocyte colony–stimulating factor, and soluble Fas.
Measurements and Main Results:We identified a two-
biomarker model in the derivation cohort that predicted
mortality (area under the receiver operator characteristic curve
[AUC], 0.79; 95% confidence interval [CI], 0.74–0.83). It
performed well in the internal test cohort (AUC, 0.75; 95% CI,
0.65–0.85) and the external validation cohort (AUC, 0.77;
95% CI, 0.72–0.83). We determined a model score threshold
demonstrating high negative predictive value (0.95) for death.
In addition to a low risk of death, patients below this threshold
had shorter ICU length of stay, lower incidence of acute kidney
injury, acute respiratory distress syndrome, and need for
vasopressors.
Conclusions:Wehave developed a simple, robust biomarker-based
model that identifies patients with SIRS/sepsis at low risk for death
and organ dysfunction.
Keywords: sepsis; systemic inflammatory response syndrome;
biomarkers; IL-8; tumor necrosis factor receptor
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Sepsis is a dysregulated response to infection
that is one of the most common reasons for
intensive care unit (ICU) admission in the
United States and a major cause of mortality
in critically ill populations worldwide (1–5).
The systemic inflammatory response
syndrome (SIRS) criteria, designed to
encapsulate the physiologic response to
critical illness, have been part of the sepsis
definition for more than two decades (6, 7).
Recent proposed changes to this definition
reflect the need to better stratify patient risk
in a heterogeneous syndrome (8). The
Acute Physiology and Chronic Health
Evaluation (APACHE) III score is a well-
validated predictor of hospital mortality in
ICU patients, but calculation of the score
requires extensive clinical data collected
over the first 24 hours of admission,
thereby limiting its utility for bedside
decision-making (9). Identification of
patients at low risk for mortality or organ
dysfunction in sepsis may improve resource
use and allow for more targeted approaches
for rational clinical trials.
Endothelial dysfunction,
inflammation, and apoptosis have been
implicated in the pathogenesis of sepsis.
Circulating biomarkers may indicate the
level of activity of these pathways and
have prognostic utility for the early
identification of patients at risk for
multiorgan dysfunction and death. Prior
work has shown that angiopoietin (Ang)-1
and Ang-2, angiogenic factors that regulate
endothelial stability and permeability,
respectively, are predictive of mortality in
patients with severe sepsis (10, 11).
Circulating levels of inflammatory
pathway proteins IL-6, IL-8, and soluble
tumor necrosis factor-a receptor 1
(sTNFR-1) have been shown to predict
mortality or organ dysfunction in patients
with established septic shock (12–16).
Apoptosis has also been implicated in the
pathophysiology of sepsis-related organ
failure (17, 18). We have previously shown
that early measurements of circulating
biomarkers of these pathways are
associated with mortality in patients
admitted to the ICU meeting SIRS criteria
and in patients with bacteremia (19, 20).
We hypothesized that a multiple-
biomarker-based model could estimate the
probability of 28-day mortality in a diverse
group of critically ill patients presenting
with SIRS and/or sepsis.
Some of the results of these studies have
been previously reported in the form of an
abstract (21).
Methods
Derivation and Internal Test Cohort
Patients were recruited between 2006 and
2010 from ICUs at Harborview Medical
Center (Seattle, WA) (19, 22). Adult
patients who met two out of four SIRS
criteria were prospectively enrolled on
admission to the ICU. We obtained plasma
specimens within 24 hours of admission to
the ICU. The study was approved by the
University of Washington Human Subjects
Research Committee and granted a waiver
of consent.
External Validation Cohort
Patients were enrolled from ICUs at
Massachusetts General Hospital (Boston,
MA) between 1999 and 2010 (23). Adult
patients were enrolled on admission to the
ICU if they had a defined risk factor for
acute respiratory distress syndrome
(ARDS) including sepsis, trauma, multiple
transfusion, or aspiration. Plasma
specimens were obtained within 48 hours
of ICU admission (24). This study was
approved by the Massachusetts General
Hospital Human Subjects Research
Committee and signed consent was
obtained from each patient or legal
surrogate.
Biomarker Measurement
Plasma concentrations of Ang-1, Ang-2,
IL-6, IL-8, sTNFR-1, soluble vascular cell
adhesion molecule-1 (sVCAM-1),
granulocyte colony–stimulating factor, and
soluble Fas were measured using an
immunoassay-based method (Meso Scale
Discovery, Rockville, MD) (19). We
assigned the lower limit or upper limit of
detection to samples that fell below or
above the range of detection, respectively.
The detection limits and number of samples
below or above the limits of detection are
available in the online supplement METHODS
section and Table E1.
Model Selection and Development
Models were constructed from the log10-
transformed biomarkers and the covariates
of age, sex, source of ICU admission
(medical/surgical), diabetes, chronic kidney
disease, cirrhosis, and body mass index
(Figure 1).
Our primary outcome of interest was
inpatient mortality at Day 28 after
enrollment. The initial model-building
methodology used least absolute shrinkage
and selection operator (LASSO) (25). The
LASSO is a model-building strategy that
performs variable selection by constraining
the sum of the regression coefficients,
thereby selecting variables for the model
and penalizing less predictive variables to
prevent overfitting. We subsequently
identified the best two-biomarker model
using all subsets selection logistic
regression. We also considered the
Sequential Organ Failure Assessment score
(SOFA) as a continuous variable to predict
mortality (26). Discrimination power was
quantified using C statistics (area under the
receiver operating characteristic curve
[AUC]) and appropriate goodness of fit was
verified via Hosmer-Lemeshow chi-square
statistics (27).
We compared the capability of these
models with APACHE III to predict
28-day mortality using the 95% confidence
interval (CI) for the difference in the AUC
(28, 29). Akaike information criterion
values were calculated to assess relative
goodness of fit of the models (30). We
performed a sensitivity analysis to see how
the models performed when limited to
At a Glance Commentary
Scientific Knowledge on the
Subject: The accurate identification
of critically ill patients with systemic
inflammatory response syndrome or
sepsis at low risk for death is an
impediment to optimal allocation of
resources and triage in this population.
What This Study Adds to the
Field: This study develops and
validates a prediction model for death
in critically ill patients with systemic
inflammatory response syndrome
based on plasma levels of two
biomarkers: IL-8 and soluble tumor
necrosis factor receptor-1, measured
early in their intensive care unit
admission. This model identifies
patients at low risk of death and who
have a lower incidence of acute kidney
injury, acute respiratory distress
syndrome, and shock.
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patients with sepsis. Sepsis was defined
as “Sepsis-2” for patients who met two
or more SIRS criteria with suspected
infection (7) or as “Sepsis-3” for patients
who had a Day 0 SOFA score of greater
than or equal to 2 with suspected infection (8).
We identified a threshold score for the
mortality prediction model to maximize
positive predictive value (PPV) defined as
the probability of those with a score above
the threshold dying within 28 days. We
also identified a threshold score that gave
a negative predictive value (NPV) of 0.95,
where NPV is defined as the probability of
those with a score below the threshold not
dying within 28 days.
Analysis of Organ Failure
We compared the extent of persistent
organ dysfunction (Day 4) (31) or length of
stay among survivors in those falling above
or below the NPV threshold using a
Wilcoxon rank sum test. We compared
proportions of ARDS (Berlin criteria
within the first 7 d) (32), severe acute
kidney injury (AKI; Acute Kidney Injury
Network score >2) (18), or cardiovascular
dysfunction (need for vasopressors within
first 72 h), or any combination of these
three endpoints.
Two sided P values of P less than 0.05
were considered significant. All statistical
analyses were performed in R (R Core
Team 2015) (33). Additional details
regarding patient enrollment, biomarker
measurement, and model development are
detailed in the online supplement.
Results
Patients in the derivation (n = 888),
internal test (n = 278), and external
validation cohorts (n = 759) were
predominantly male and middle aged
(Table 1). The derivation cohort
comprised white persons previously used
in genetic studies from our group (19),
whereas the internal test cohort was
nonwhite and the external validation
cohort was of diverse race. The derivation
cohort was comprised of a mixed medical
(n = 480; 54%) and surgical population
(n = 408; 46%), whereas the internal test
cohort and external validation cohort
were predominantly medical ICU patients
(n = 215, 77% and n = 718, 95%,
respectively). Most of the patients in
all three cohorts met the definition of
Sepsis-2 or Sepsis-3 (7, 8). The 28-day
mortality was 12% in the derivation
cohort (n = 104), 9% in the test cohort
(n = 25), and 13% in the external
validation cohort (n = 97). The distribution
of the biomarker concentrations (median
and interquartile range) are listed in
Table E2.
Mortality Prediction Model Derivation
We first developed the prediction model in
the derivation cohort. We included age, sex,
Variables for model building: log10-transformed
biomarkers, age, gender, source of ICU admission
(medical/surgical), diabetes, CKD, cirrhosis, and BMI
Biomarkers: IL-6, IL-8, sTNFR-1, G-CSF, sVCAM-1,
Ang-1, Ang-2, the ratio of Ang-2/Ang-1, and sFas*
Best two biomarker model by
all-subsets logistic regression
5 subjects without complete clinical data
55 subjects without sufficient plasma sample
5 Biomarkers selected
by LASSO in Derivation
Performance evaluated:
Internal Test Cohort
278 subjects
Performance evaluated:
External Validation
759 subjects
Derivation Cohort
948 subjects
888 subjects with biomarkers measured
Figure 1. Sample and statistical flow diagram for mortality prediction model. Subject numbers for the
development and validation of the least absolute shrinkage and selection operator or all subsets
selection logistic regression models for 28-day mortality. *Lower limit or upper limit of detection
applied to samples falling below or above the range of detection. Ang = angiopoietin; BMI = body
mass index; CKD = chronic kidney disease; G-CSF = granulocyte colony–stimulating factor; ICU =
intensive care unit; LASSO = least absolute shrinkage and selection operator; sVCAM= soluble
vascular cell adhesion molecule; TNFR = tumor necrosis factor receptor.
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source of ICU admission (medical/surgical),
diabetes, chronic kidney disease, cirrhosis,
and body mass index, and log10-
transformed IL-6, IL-8, sTNFR-1,
granulocyte colony–stimulating factor,
sVCAM-1, Ang-1, Ang-2, the ratio of Ang-
2/Ang-1, and soluble Fas as candidate
predictors of mortality. In the derivation
cohort, a LASSO model including the
combination of IL-8, sTNFR-1, Ang-2,
Ang-2/Ang-1, and sVCAM-1 most
accurately predicted mortality (AUC, 0.80;
95% CI,0.75–0.84) (see Figure E1). Notably,
clinical variables were excluded from the
LASSO model. The performance of this
model was comparable with APACHE III
(AUC, 0.75; 95% CI, 0.70–0.80) (Table 2).
There was no significant difference between
the LASSO model and APACHE III (95%
CI for difference, 20.03 to 0.11). The
LASSO model combined with APACHE III
significantly improved the discrimination
(0.84; 95% CI, 0.80–0.88) above that of the
APACHE III score alone (95% CI for
difference, 0.01–0.16); however, this model
was not a good fit on the basis of the
Hosmer-Lemeshow test and may not be
reliable (Table 2). Table E3 shows the
predictive capacity for each of the
individual biomarkers.
We then sought the most
parsimonious model using one, two, three,
or four biomarkers. A two-biomarker
model of IL-8 and sTNFR-1 demonstrated
an AUC of 0.79 (95% CI, 0.74–0.83)
(Figure 2A) and improved on a single
biomarker model (AUC, 0.77; 95% CI,
0.73–0.82) (see Figure E2) but addition
of other biomarkers added only small
incremental value (see Figure E2, Table
E4). The two-biomarker model of IL-8 and
sTNFR-1 performed similarly to APACHE
III score (AUC, 0.75; 95% CI, 0.70–0.80)
(Table 2) and better than Day 0 SOFA
score as a continuous variable (AUC, 0.71;
95% CI, 0.66–0.76). In a sensitivity
analysis using inpatient mortality rather
than 28-day inpatient mortality the AUCs
for APACHE III score and our two-
biomarker model were unchanged. The
two-biomarker model was carried forward
for internal and external validation.
Mortality Prediction Model Testing
and Validation
We tested the ability of the two biomarker
model with IL-8 and sTNFR-1 to
discriminate 28-day mortality in an
internal test and external validation cohort.
The AUC in the internal test cohort was
0.75 (95% CI, 0.65–0.85) (Figure 2B) and
in the external validation cohort was 0.77
(95% CI, 0.72–0.83) (Figure 2C). This
performed similarly to APACHE III in the
internal test cohort (AUC, 0.77; 95% CI,
0.68–0.86) (Figure 2B) and in the external
validation cohort (0.83; 95% CI,
0.79–0.87) (Figure 2C). Adding our two-
biomarker model to APACHE III slightly
improved the performance above
APACHE III alone in the derivation
(AUC, 0.83 [95% CI, 0.80–0.87] vs.
AUC, 0.75 [95% CI, 0.70–0.80]; difference
of 0.08 [95% CI, 0.004–0.15]), but
not in the internal test (AUC, 0.79
[95% CI, 0.70–0.88] vs. AUC, 0.77 [95%
CI, 0.68–0.86]; difference of 0.03 [95% CI,
20.14 to 0.20]) or external validation
cohort (AUC, 0.82 [95% CI, 0.77–0.87] vs.
0.83 [95% CI, 0.79–0.87]; difference of
0.03 [95% CI, 20.05 to 0.11]) (Table 2).
For comparison, a Day 0 SOFA score of
2 or greater, recently proposed as a new
criteria for sepsis in the ICU (34) and
shown to predict mortality in a general
ICU population, has a maximum AUC in
these cohorts of 0.60 (see Figure E1).
When SOFA was considered as a
continuous variable for mortality
prediction, it performed similarly to the
two-biomarker model in the internal test
cohort (AUC, 0.75; 95% CI, 0.66–0.84).
SOFA was not as predictive as the two-
biomarker model in the external
validation cohort (AUC, 0.67; 95% CI,
0.61–0.73) (Table 2) and was not a good fit
on the basis of the Hosmer-Lemeshow test
(P, 0.001).
We performed sensitivity analyses to
test our ability to discriminate mortality
when limiting to patients with sepsis defined
as Sepsis-2 and Sepsis-3 in all cohorts. When
limited to patients with either definition of
sepsis, we found that the combination of
IL-8 and sTNFR-1 predicted mortality with
similar AUC values (see Figure E3).
Based on our model using IL-8 and
sTNFR-1, we observed increasing mortality
for each quartile of model score in the
Table 1. Subject Characteristics
Derivation
(n = 888)
Internal Test
(n = 278)
External Validation
(n = 759)
Age, yr, mean6 SD 566 16 546 16 616 18
Male, n (%) 564 (64) 199 (72) 487 (64)
Race, n (%)
White 888 (100) 0 (0) 696 (92)
African American 0 (0) 145 (52) 21 (2.8)
Asian/Pacific Islander 0 (0) 90 (32) 29 (3.8)
Native American 0 (0) 43 (15) 1 (0.13)
BMI, kg/m2, mean6 SD 306 10 316 23 286 8
Comorbidities, n (%)
Diabetes 221 (25) 104 (37) 200 (26)
Cirrhosis 75 (8.4) 17 (6.1) 28 (3.7)
Chronic kidney disease 63 (7.1) 36 (13) —
Source of ICU admit, n (%)
Medical 480 (54) 215 (77) 718 (95)
Surgical 408 (46) 63 (23) 41 (5.4)
Day 0 SOFA >2, n (%)* 703 (79) 229 (82) 749 (99)
Source of critical illness, n (%)†
Sepsis-2 698 (79) 206 (74) 614 (81)
Sepsis-3 566 (64) 177 (64) 604 (80)
Pneumonia 179 (20) 72 (26) 340 (45)
Other 299 (34) 95 (34) 145 (19)
APACHE III, mean6 SD 516 26 516 26 676 25
Day 4 SOFA score, mean6 SD 3.06 2.9 3.16 3.2 —
ICU LOS among survivors‡,
d, mean6 SD
7.76 11 7.46 10 6.56 6.9
28-d mortality, n (%) 104 (12) 25 (9) 97 (13)
Definition of abbreviations: APACHE = Acute Physiology and Chronic Health Evaluation; BMI = body
mass index; ICU = intensive care unit; LOS = length of stay; SOFA = Sequential Organ Failure
Assessment.
*SOFA scores greater than or equal to 2 on Day 0.
†Source of critical illness is not mutually exclusive.
‡ICU LOS among patients who survived 28 days.
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discovery, internal test, and external
validation cohort (see Table E5). We
derived PPV and NPV for mortality
(Table 3). A model score threshold of 0.54
maximized the PPV in the derivation
cohort at 0.6 (Table 3). A model score
below the threshold of 0.135 had an NPV of
0.95 in the derivation cohort that was
identical in the internal test dataset (NPV,
0.95) and similar in the external validation
cohort (NPV, 0.93).
Other ICU Outcomes
Although mortality is a relevant endpoint,
other outcomes including organ dysfunction
and ICU length of stay are clinically
important. Need for vasopressors, AKI, and
ARDS are clinical factors that often warrant
admission to the ICU. We wanted to
characterize whether patients above or
below the model score threshold derived to
maximize NPV for mortality had differences
in these outcomes. In the derivation cohort,
246 patients had scores less than 0.135,
whereas 642 patients had model scores
greater than 0.135. Patients below the
threshold had lower median SOFA scores at
4 days (2 vs. 4; P, 0.001) (see Figure E4A)
and among survivors, lower median length
of ICU stay (4 d vs. 7 d; P, 0.001) (see
Figure E4B). The internal test cohort
patients (n = 78) below the threshold also
had lower median Day 4 SOFA scores (4 vs. 5;
P, 0.001) and lower median ICU length of
stay (4 d vs. 5 d; P, 0.001). The external
validation cohort patients below the
threshold (n = 229) had lower ICU length
of stay (3 d vs. 6 d; P, 0.001). Day 4 SOFA
scores were not available for the external
validation cohort.
We also examined the proportions of
patients above and below the model
threshold with either AKI, need for
vasopressors within 72 hours, or ARDS
within 7 days of ICU admission. Among
patients with scores below the threshold
(0.135) in the derivation, internal test, and
external validation cohorts, there was a
lower proportion of each ICU-defining
Table 2. Model Performance in Derivation, Test, and Validation Cohorts
Derivation Internal Test External Validation
AUC HL*
Difference in
AUC (95% CI) AUC HL*
Difference in
AUC (95% CI) AUC HL*
Difference in
AUC (95% CI)
LASSO 0.80 (0.75 to 0.84) 0.31 0.04 (20.03 to 0.11) 0.77 (0.66 to 0.87) 0.01 0.01 (20.15 to 0.16) NA NA NA
Two-biomarker 0.79 (0.74 to 0.83) 0.46 0.03 (20.04 to 0.10) 0.75 (0.65 to 0.85) 0.16 20.03 (20.18 to 0.13) 0.77 (0.72 to 0.83) 0.09 20.04 (20.12 to 0.04)
Day 0 SOFA† 0.71 (0.66 to 0.76) 0.36 0.04 (20.04 to 0.12) 0.75 (0.65 to 0.85) 0.53 0.02 (20.13 to 0.17) 0.67 (0.61 to 0.73) ,0.001 20.16 (20.08 to 20.24)
APACHE III 0.75 (0.70 to 0.80) 0.32 — 0.77 (0.68 to 0.86) 0.37 — 0.83 (0.79 to 0.87) 0.11 —
LASSO1APACHE III 0.84 (0.80 to 0.88) 0.03 0.08 (0.01 to 0.16) 0.80 (0.69 to 0.90) 0.2 0.05 (20.12 to 0.22) NA NA NA
Two-biomarker1
APACHE III
0.83 (0.80 to 0.87) 0.09 0.08 (0.004 to 0.15) 0.79 (0.70 to 0.88) 0.57 0.03 (20.14 to 0.20) 0.82 (0.77 to 0.87) 0.13 0.03 (20.05 to 0.11)
Definition of abbreviations: APACHE = Acute Physiology and Chronic Health Evaluation; AUC = area under the receiver operator characteristic curve;
CI = confidence interval; HL = Hosmer-Lemeshow; LASSO= least absolute shrinkage and selection operator; NA = biomarkers not available to calculate
the model; SOFA = Sequential Organ Failure Assessment.
*Chi-square value (P value) from HL test with 10 bins. The model is rejected if P value is ,0.05.
†SOFA score on Day 0.
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Figure 2. Receiver operating curves for mortality prediction models. Area under the receiver
operating characteristic curve (AUC) for mortality in the (A) derivation cohort, (B) internal test cohort,
and (C) external validation cohort. AUC values are presented with 95% confidence intervals in
parenthesis. The models are shown as TNFR1 IL8 to represent the model of two biomarkers alone,
Acute Physiology and Chronic Health Evaluation III (APC3), and TNFR1 IL81 APC3 for the
combined model of biomarkers and APC3. TNFR = tumor necrosis factor receptor.
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illness compared with patients with scores
above the threshold (Table 4). The most
dramatic example is the proportion of
patients with severe AKI (Acute Kidney
Injury Network score >2), which was 0.05
for patients below the threshold, but was
0.37 for patients above the threshold.
Discussion
In this study, we show that a simple predictive
model based on early plasmameasurements of
IL-8 and sTNFR-1 predicts mortality in a
diverse group of critically ill patients meeting
criteria for SIRS at two academic medical
centers. To our knowledge, this is the largest
and most inclusive study of a predictive
biomarker model in SIRS/sepsis.
Prior reports in smaller groups of
patients have suggested the potential utility
of sTNFR-1 and IL-8 for prediction of
mortality in patients with sepsis. A small
single center study (n = 52) in adult
patients with septic shock showed that
circulating sTNFR-1 levels were modestly
predictive of mortality and that sTNFR-1
levels remained elevated in nonsurvivors
compared with survivors for 48 hours (14).
In patients with ARDS inclusion
of circulating sTNFR-1 levels in a
multibiomarker prediction model was
predictive of death (35). IL-8 was also
included in a multiple-biomarker decision
tree model designed to predict mortality
in adult and pediatric patients with septic
shock (13, 36) and adult patients with
ARDS (35). Low levels of IL-8 in a
pediatric septic shock cohort predicted a
high likelihood of survival (37). In
contrast, our study used sTNFR-1 and
IL-8 in a simple two-biomarker predictive
model in two large cohorts of ICU
patients with SIRS/sepsis. IL-8 and
sTNFR-1 were among biomarkers shown
by latent class analysis to distinguish a
subphenotype of ARDS that has differential
mortality and responsiveness to fluid
management strategies (35, 38). This suggests
that these biomarkers could be considered
to better understand subphenotypes or
predictive enrichment of treatment
responsiveness in sepsis (39).
Our model is comparable with
APACHE III in terms of mortality
prediction in the three cohorts. Notably, the
APACHE III score requires measurement of
multiple variables over a 24-hour time
period, limiting its utility for early clinical
decision-making. Thus, our simple model
may represent a good alternative for early
mortality prediction in this patient
population. In addition, our biomarker
model could be developed for rapid point-
of-care testing moving closer toward a goal
of precision medicine.
Table 3. Negative and Positive Predictive Values for the Two-Biomarker Model
Cohort
Threshold
Goal
Model Score
Threshold*
Patients above/below
Threshold (n) PPV† NPV‡
Derivation NPV 0.135 642/246 0.29 0.95
PPV 0.540 868/20 0.60 0.89
Internal test NPV 0.135 200/78 0.18 0.95
PPV 0.540 272/6 0.50 0.92
External validation NPV 0.135 530/229 0.29 0.93
PPV 0.540 747/12 0.83 0.88
Definition of abbreviations: NPV = negative predictive value; PPV = positive predictive value; sTNFR-
1 = soluble tumor necrosis factor receptor 1.
*Model score threshold obtained from model fit to the discovery dataset using IL-8 and sTNFR-1 [logit
(probability of death) = 212.81 2.363 log10(sTNFR-1 concentration)1 0.803 log10(IL-8 concentration)].
†PPV is the probability of those with a score above the threshold dying within 28 days.
‡NPV is the probability of those with a score below the threshold not dying within 28 days.
Table 4. Proportions of Severe Organ Dysfunction among Patients below or above the Model Threshold
Model Score below 0.135 Model Score above 0.135
All Subjects: Total
Observations
Patients with
Outcome
Total with
Observation* Prop†
Patients with
Outcome
Total with
Observation‡ Prop†
ARDS in 7 dx
Derivation 116 642 0.18 52 246 0.21 888
Internal test 39 203 0.19 25 75 0.33 278
External validation 30 460 0.07 41 299 0.14 759
AKI (AKIN >2)jj
Derivation 34 639 0.05 88 241 0.37 880
Internal test 13 200 0.06 41 75 0.55 275
External validation 3 198 0.02 48 179 0.27 377
Shock¶
Derivation 109 642 0.17 97 246 0.39 888
Internal test 33 203 0.16 31 75 0.41 278
External validation 150 373 0.40 153 248 0.62 621
Definition of abbreviations: AKI = acute kidney injury; AKIN = Acute Kidney Injury Network; ARDS = acute respiratory distress syndrome; Prop = proportion.
*Number of patients with score below 0.135 with organ failure data available for analysis.
†Proportion of subjects with outcome.
‡Number of subjects with score above 0.135 with organ failure data available for analysis.
xPresence of ARDS within 7 days as defined by Berlin criteria.
jjSevere AKI as defined by an AKIN score >2.
¶Vasopressors required in first 72 hours of admission.
ORIGINAL ARTICLE
Mikacenic, Price, Harju-Baker, et al.: Biomarkers Predict Sepsis Mortality 1009
The clinical definition of sepsis is in a
state of evolution. Proposed changes have
moved from SIRS criteria (Sepsis-2) to
an approach based on manifestations of
organ dysfunction (Sepsis-3) (6–8). Part
of the rationale is that SIRS criteria may
not be effective because they define a
heterogeneous population that may not be
at elevated risk for adverse outcomes (40,
41). Notably, in contrast to the recent
publication supporting the Sepsis-3 criteria,
in our cohorts a SOFA score on Day 0 of 2
or greater was a poor predictor of mortality
(34). Using SOFA score as a continuous
variable increased its predictive capacity,
but the biomarker model still outperformed
the SOFA in the derivation and external
validation cohorts. This may be explained
by differences in underlying diagnoses and
our inclusion criteria that mandated
presence of SIRS criteria on enrollment
resulting in a more severely ill population
or decreased specificity of the Sepsis-3
definition. Regardless, the strong
performance of our model using both
definitions of sepsis suggests that it will be
robust when applied to other sepsis
populations.
The most straightforward application
of our model would be in the identification
of patients at low risk of death and organ
dysfunction. We identified a model score
threshold that had an NPV for mortality in
the derivation/test cohorts of 0.95 and
remained high in the validation cohort
(0.93). Patients below the same threshold
had less persistent organ dysfunction
measured by Day 4 total SOFA score,
proportionally less AKI, need for
vasopressors, ARDS, and among survivors,
shorter ICU length of stay. Our model built
for maximizing NPV for mortality
distinguishes certain organ failure, such as
AKI, better than shock. Future models
should be built directly for organ failure to
maximize the utility of these biomarkers as
a clinical tool. Taken together, these
findings suggest that our model might be
helpful to clinicians in early triage decisions
in patients with sepsis and to assist
researchers in rational enrollment for
clinical trials.
Our study has several limitations. First,
we studied only patients who met SIRS
criteria and were admitted to the ICU at
academic medical centers. This limits the
generalization of our results to a broader set
of critically ill patients. Second, we did not
include several clinical measurements
commonly used for assessment of severity
including arterial lactate, procalcitonin,
or C-reactive protein (42–46). However,
lactate measurements were not included
in the recently proposed sepsis definition
for the lack of improvement in predictive
capacity above the proposed model and
procalcitonin has not shown strong
evidence of predictive utility as a stand-
alone biomarker (8, 34, 47). Third, our
external validation cohort was recruited
over an extended period of time. This may
lead to heterogeneity in clinical treatment
over that time frame. Nonetheless, our
model performs well despite that
heterogeneity. Finally, although in this
study we aimed for a parsimonious and
easily clinically applicable model, other
biomarkers (IL-6, Ang-1, Ang-2, sVCAM-1)
did have some, albeit limited, incremental
prognostic value. Future studies need
to explore whether other biomarkers
might provide additional value,
particularly for specific forms of
organ dysfunction.
In summary, we have developed and
validated a robust biomarker-based model
that predicts mortality in a large
heterogeneous population of critically ill
patients with SIRS/sepsis. This algorithm
could potentially be incorporated in either
laboratory-based or point-of-care
diagnostics to guide management of
critically ill patients. Future studies will
explore whether our model can improve
early clinical decision-making in patients
with sepsis. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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